Patents Assigned to Synthelabo
  • Patent number: 6541643
    Abstract: The invention relates to a process for the preparation of spiro[cis-4-(&bgr;-hydroxyethyloxy)cyclohexane-[3H]indol]-2′[1′H]-one derivatives of the formula (I) wherein R1 and R2 are as defined herein, by reduction of a dispiro[(1,3-dioxolane)-2,4′-cyclohexane-1′3′-[3H]indol]-2″[1″H]-one derivative of general formula (II), wherein R1 and R2 are as defined herein, which comprises carrying out the reduction (a) with sodium cyanoborohydride in the presence of a Lewis acid, or (b) with sodium borohydride in the presence of a strong acid.
    Type: Grant
    Filed: April 17, 2002
    Date of Patent: April 1, 2003
    Assignee: Sanofi-Synthelabo
    Inventors: Gergely Héja, Éva Csikós, Csaba Gönczi, Judit Halász, Félix Hajdú, István Hermecz, László Kis, Lajos Nagy, Andrea Sántáné Csutor, Kálmán Simon, Tiborné Szomor, Györgyné Szvoboda
  • Patent number: 6538003
    Abstract: The invention relates to pyridopyranoazepine derivatives, to pharmaceutical compositions containing them, to processes for preparing them, and to the method of use thereof in the treatment or prevention of disorders associated with a dysfunction of the nicotine receptors.
    Type: Grant
    Filed: August 17, 2001
    Date of Patent: March 25, 2003
    Assignee: Sanofi-Synthelabo
    Inventors: Frédéric Galli, Samir Jegham, Alistair Lochead, Axelle Samson
  • Patent number: 6534481
    Abstract: A synthetic polysaccharide including an antithrombin III binding domain consisting of a concatenation of five monosaccharides supporting a total of two carboxylic acid functions and at least four sulpho groups, said domain being directly bound at the non-reducing end by a thrombin binding domain including a concatenation of 10-25 monosaccharide units selected from hexoses, pentoses or deoxy sugars of which all the hydroxyl groups are etherified by a C1-6 alkyl group or esterified in the form of sulpho groups, as well as salts and particularly pharmaceutically acceptable salts thereof, are disclosed.
    Type: Grant
    Filed: September 7, 1999
    Date of Patent: March 18, 2003
    Assignees: Sanofi-Synthelabo, Akzo Nobel
    Inventors: Pierre Alexandre Driguez, Philippe Duchaussoy, Jean Marc Herbert, Maurice Petitou, Constant Van Boeckel, Peter Grootenhuis, Johannes Basten, Cornelia Dreef-Tromp
  • Patent number: 6528497
    Abstract: Novel synthetic polysaccharides for use in the treatment of pathologies associated with a coagulation dysfunction.
    Type: Grant
    Filed: September 5, 2000
    Date of Patent: March 4, 2003
    Assignees: Sanofi-Synthelabo, Akzo Nobel N.V.
    Inventors: Johannes Basten, Cornelia Dreef-Tromp, Pierre Alexandre Driguez, Philippe Duchaussoy, Jean Marc Herbert, Maurice Petitou, Constant Van Boeckel
  • Patent number: 6528539
    Abstract: The invention relates to a stable fumagillin formulation and to the method of use thereof in treating and/or combating intestinal infections.
    Type: Grant
    Filed: October 15, 2001
    Date of Patent: March 4, 2003
    Assignee: Sanofi-Synthelabo
    Inventors: Bernard Abramovici, Jean-Luc Dubois
  • Patent number: 6521764
    Abstract: The invention relates to a process for the preparation of Fumagillin by liberation from its salt characterized by reacting Fumagillin dicyclohexylamine salt with an organic acid in alcoholic medium.
    Type: Grant
    Filed: March 5, 2002
    Date of Patent: February 18, 2003
    Assignee: Sanofi-Synthelabo
    Inventors: Gyula Farkas, Andrea Györbiró, István Hermecz, Kálmán Simon, Anna Szabó, Árpádné Vasvári
  • Patent number: 6514531
    Abstract: The present invention relates to controlled-release dosage forms of zolpidem or salts thereof adapted to release zolpidem over a predetermined time period, according to a biphasic profile of dissolution, where the first phase is an immediate release phase and the second phase is a prolonged release phase and particular embodiments thereof intended to avoid abuse.
    Type: Grant
    Filed: July 16, 2001
    Date of Patent: February 4, 2003
    Assignee: Sanofi-Synthelabo
    Inventors: Gérard Alaux, Gareth Lewis, Frédéric Andre
  • Patent number: 6506750
    Abstract: N-(phenylacetyl)morpholine derivatives useful as NK1 receptor antagonists, a process for the preparation thereof, and pharmaceutical compositions containing them as active principle.
    Type: Grant
    Filed: September 24, 2001
    Date of Patent: January 14, 2003
    Assignee: Sanofi-Synthelabo
    Inventors: Jean-Philippe Ducoux, Xavier Emonds-Alt, Patrick Gueule, Vincenzo Proietto
  • Patent number: 6504030
    Abstract: Novel orthorombic polymorph of clopidogrel hydrogen sulfate or hydrogen sulfate of methyl (+)-(S)-&agr;-(2-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine-5-acetate and a process for its preparation
    Type: Grant
    Filed: June 21, 2002
    Date of Patent: January 7, 2003
    Assignee: Sanofi-Synthelabo
    Inventors: André Bousquet, Bertrand Castro, Jean Saint-Germain
  • Patent number: 6489334
    Abstract: The invention relates to a method of crystallizing a tetrahydropyridine derivative, to the novel crystalline forms thereby obtained and to the pharmaceutical compositions containing said tetrahydropyridine derivative in a given crystalline form as the active principle.
    Type: Grant
    Filed: September 6, 2001
    Date of Patent: December 3, 2002
    Assignee: Sanofi-Synthelabo
    Inventors: Antoine Caron, Bruno Franc, Olivier Monnier
  • Patent number: 6482986
    Abstract: The invention concerns compounds of formula (I) wherein A, X, Y, n, R1, R2 and R3 are as defined in claim 1. Said compounds are specifically binding to sigma receptors particularly those of the peripheral nervous system.
    Type: Grant
    Filed: February 27, 2002
    Date of Patent: November 19, 2002
    Assignee: Sanofi-Synthelabo
    Inventors: Robert Boigegrain, Bernard Bourrie, Martine Bourrie, Pierre Casellas, Jean Marc Herbert, Pierre Lair, Dino Nisato, Raymond Paul, Jean Claude Vernieres
  • Publication number: 20020160981
    Abstract: The invention relates to the use of a synthetic oligosaccharide which is a selective inhibitor of factor Xa acting via antithrombin III, alone or in association with aspirin, for the preparation of medicaments intended for preventing or treating thromboembolic diseases occurring in a mammal which has undergone a percutaneous transluminal angioplasty.
    Type: Application
    Filed: May 28, 2002
    Publication date: October 31, 2002
    Applicant: Sanofi-Synthelabo
    Inventors: Roger Guilcaume Cariou, Jacobus Christianus Johannes Stiekema
  • Patent number: 6469173
    Abstract: The invention relates to lower-alkyl esters of 3-(3,4-dihalophenyl)-2,6-dioxopiperidine-3-propionic acid derivatives, and to processes for preparing the same.
    Type: Grant
    Filed: June 12, 2001
    Date of Patent: October 22, 2002
    Assignee: Sanofi-Synthelabo
    Inventors: Bertrand Castro, Jean-Robert Dormoy, Alain Rabion
  • Patent number: 6463618
    Abstract: A toothbrush, of the type in which a brush head is equipped with flexible friction rods which include a lower anchoring foot by fastening the rods to a principal body of the head, the anchoring foot of at least some of the rods is received in an anchoring hole passing through the principal body in such a way that upper and lower ends of the anchoring foot are arranged above and below the upper and lower faces, respectively, of the principal body, an upper end of an anchoring foot is connected to a lower end by a bridge of material which extends outside the anchoring hole and, at the lower and upper ends of the anchoring foot, the bridge of material bears against the lower and upper faces, respectively, of the principal body in order to fasten the rods to the head.
    Type: Grant
    Filed: September 18, 2000
    Date of Patent: October 15, 2002
    Assignee: Sanofi-Synthelabo
    Inventor: Bertrand Zimmer
  • Patent number: 6465489
    Abstract: The invention concerns compounds of formula (I) in racemic or optically pure form, methods for obtaining them and pharmaceutical compositions containing same. Said compounds are selective NK3 receptor antagonists.
    Type: Grant
    Filed: April 5, 2001
    Date of Patent: October 15, 2002
    Assignee: Sanofi-Synthelabo
    Inventors: Alain Aulombard, Xavier Emonds-Alt, Vincenzo Proietto, Didier Van Broeck
  • Patent number: 6451795
    Abstract: 4-Oxo-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-carboxamide derivatives having affinity for the peripheral benzodiazepine receptors are useful for the prevention or treatment of peripheral neuropathies and for the treatment of central neurogenerative diseases.
    Type: Grant
    Filed: July 25, 2001
    Date of Patent: September 17, 2002
    Assignee: Sanofi-Synthelabo
    Inventors: Frank Marguet, Jacques Froissant, Régine Bartsch-Li, Benoît Marabout, Mireille Sevrin
  • Patent number: 6452012
    Abstract: This invention relates to 3-(3-phenyl-2,6-dioxopiperidin-3-yl) propionamide derivatives, and to processes for preparing the same.
    Type: Grant
    Filed: November 13, 2001
    Date of Patent: September 17, 2002
    Assignee: Sanofi-Synthelabo
    Inventors: Bertrand Castro, Hélène Mattras, Aldo Previero
  • Patent number: 6447480
    Abstract: The invention relates to an injection device comprising a syringe body (1), which delimits a chamber which is designed to be filled with liquid, and a unit (25) for distributing the liquid, comprising an end piece for closing off the said chamber, which is extended by a base, which supports an injection needle which is protected by a protective cap (35), the said distribution unit being mobile axially between a closing-off position of the chamber, and a position for injection of the liquid. According to the invention, the unit (25) for distributing comprises an intermediate section (31) between the base and the closing-off end piece, and the syringe body (1) comprises a ring (6) which delimits two superimposed compartments (18, 19), which can each accommodate the said intermediate section.
    Type: Grant
    Filed: April 2, 2001
    Date of Patent: September 10, 2002
    Assignee: Sanofi-Synthelabo
    Inventor: Marc Brunel
  • Patent number: 6433185
    Abstract: The invention relates to compounds of formula in which R1 to R9, R16 and R17 are as defined in claim 1. These compounds are pharmacologically active.
    Type: Grant
    Filed: September 6, 2001
    Date of Patent: August 13, 2002
    Assignee: Sanofi-Synthelabo
    Inventors: Bernard Ferrari, Jean Gougat, Claude Muneaux, Yvette Muneaux, Pierre Perreaut, Claudine Planchenault
  • Patent number: D461720
    Type: Grant
    Filed: November 10, 1999
    Date of Patent: August 20, 2002
    Assignee: Sanofi-Synthelabo
    Inventor: Fabrice Peltier